2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2143

Neuromyelitis Optica Overlaps Frequently with Systemic Rheumatic Diseases in African-Americans: Experience at a Large US Academic Medical Center
Abstract Number: 706

Neuronal BC RNAs: Systemic Lupus Erythematosus Autoantibodies Cause Dendritic Transport Impairments
Abstract Number: 379

Neurosarcoidosis: An Evaluation Based on the Neurosarcoidosis Consortium Consensus Group
Abstract Number: 930

Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator
Abstract Number: 1226

Neutrophil Activation Identifies Patients with Active Polyarticular Gout – a Role for Neutrophil Biomarkers in Monitoring Gout Disease Activity and Severity
Abstract Number: 2789

Neutrophil Extracellular Traps Induce Tissue-Invasive Macrophages in Granulomatosis with Polyangiitis Dominated by Ear, Nose and Throat Manifestations
Abstract Number: 685

Neutrophil Lymphocyte Ratio as a Marker for Immune Complex-Driven Inflammation in Patients with Systemic Lupus Erythematosus
Abstract Number: 2804

Neutrophil Passage Through the Megakaryocyte Cytoplasm via Emperipolesis Modulates Neutrophil Migration
Abstract Number: 1023

Neutrophils Are an Important Source of Microparticles in Lupus and Asymptomatic ANA+ Individuals
Abstract Number: 1469

New 2019 SLE EULAR/ACR Classification Criteria for SLE Are Valuable for Distinguishing Patients with SLE from Patients with pSS in Daily Practice
Abstract Number: 1274

New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody
Abstract Number: 1185

New Imaging Modality to Evaluate Arthritis in Lupus Based on Frequency-domain Optical Transmission
Abstract Number: 1813

New Medications Are Needed for Children with Juvenile Idiopathic Arthritis
Abstract Number: 970

New-onset ANCA-associated Vasculitis Is Associated with Significant Phenotypic B Cell Dysfunction
Abstract Number: 653

Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: A Distinct Disease Subset from Young-onset Lupus Nephritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].